Early intensive anti-diabetic treatment may improve β-cell function

December 2008
OB/GYN Clinical Alert;Dec2008 Clinical Briefs in Primary, Vol. 13, p23
The article reports on the study which examines the effects of early anti-diabetic treatments. Newly diagnosed type 2 diabetics with severe hyperglycemia have received intensive basal-prandial insulin therapy. Once good, glycemic control was administered and they were randomized to continued maintenance of tight control with basal-prandial insulin or oral agents, metformin and sulfonylurea. The study shows that insulin has better control over β-cell than those oral agents.


Related Articles

  • ADVERSE EFFECTS OF METFORMIN IN COMBINATION WITH GLIMEPIRIDE AND GLIBENCLAMIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Pravinkumar, V. Ingle; Gokul, S. Talele // Asian Journal of Pharmaceutical & Clinical Research;Jan-Mar2012 Supplement, p108 

    In type 2 diabetes mellitus, it is considered that the lowered insulin secretion and the lowered insulin sensitivity cause hyperglycaemia. Sulfonylureas have strong blood-glucose lowering effect by stimulating insulin secretion and have been widely used in the treatment of type 2 diabetes....

  • Metformin Associated with Less Need for a Second Medicine. SHAUGHNESSY, ALLEN F. // American Family Physician;2/15/2015, Vol. 91 Issue 4, p261 

    The article discusses a study which investigated the initial treatment of type 2 diabetes using oral hypoglycemics other than metformin. Topics discussed include possible cardiovascular event in patients that initially took a sulfonylurea, higher cost of treatment associated with...

  • Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea. SCHERNTHANER, GUNTRAM; GROSS, JORGE L.; ROSENSTOCK, JULIO; GUARISCO, MICHAEL; MIN FU; YEE, JACQUELINE; MASATO KAWAGUCHI; CANOVATCHEL, WILLIAM; MEININGER, GARY // Diabetes Care;Sep2013, Vol. 36 Issue 9, p2508 

    OBJECTIVE--To evaluate the efficacy and safety of canagliflozin, a sodium glucose cotrans-porter 2 inhibitor, compared with sitagliptin in subjects with type 2 diabetes inadequately controlled with metformin plus sulfonylurea. RESEARCH DESIGN AND METHODS--In this 52-week, randomized,...

  • Safe prescribing of metformin in diabetes. Davoren, Peter // Australian Prescriber;Feb2014, Vol. 37 Issue 1, p2 

    Metformin is the first-line pharmacological therapy for type 2 diabetes. It is the only glucose-lowering oral drug that has been shown to reduce mortality in patients with diabetes. The most common adverse effect is gastrointestinal upset. Starting at a low dose and increasing it slowly reduces...

  • Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach. Singh, Awadhesh Kumar // Indian Journal of Endocrinology & Metabolism;Sep/Oct2014, Vol. 18 Issue 5, p617 

    The most commonly used oral drug in treating type 2 diabetes (T2DM) after metformin are sufonylureas (SUs) based on the confidence gained over the several decades and because of its cheaper cost. Unfortunately, SUs are associated with secondary failure and sometimes associated with therapy...

  • DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes. Sang Ah Lee // Journal of Korean Diabetes;2013, Vol. 14 Issue 3, p128 

    Dipeptidylpeptidase-4 (DPP-4) inhibitors are new glucose-lowering agents with mechanisms that differ from those of previous oral hypoglycemic agents (OHAs). DPP-4 inhibitors have shown a continuous glucose lowering effect (> 0.5%) when used in monotherapy as well as when used in combination with...

  • Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? No, It's Time to Move On! Genuth, Saul // Diabetes Care;Jan2015, Vol. 38 Issue 1, p170 

    The article discusses the research supporting the discontinuations of using sulfonylureas (SU) as a first-line add on to metformin in treating type 2 diabetes. Topics include the joint recommendations of the American Diabetes Association (ADA) and the European Association for the Study of...

  • Effect of glimepiride and nateglinide on serum insulin and glucose concentration in healthy cats. Mori, A.; Lee, P.; Yamashita, T.; Nishimaki, Y.; Oda, H.; Saeki, K.; Miki, Y.; Mizutani, H.; Ishioka, K.; Honjo, T.; Arai, T.; Sako, T. // Veterinary Research Communications;Dec2009, Vol. 33 Issue 8, p957 

    Glimepiride and nateglinide are two common oral hypoglycemic agents currently being used with humans suffering from Type 2 diabetes mellitus. Neither drug has been tested with cats thus far and it is currently unknown whether either of these drugs exert any effect in cats or not. The objective...

  • Effects of repaglinide vs glimepiride on serum glucose concentrations, HbA1c and body weight in patients with type 2 diabetes mellitus. Hani, Mohamad. Shatha // Tikrit Medical Journal;2011, Vol. 17 Issue 2, p109 

    The present study was designed to compare the efficacy of repaglinide and glimepiride in patients with type 2 DM. The study included 61 type 2 diabetic patients already on metformin therapy (850 mg daily). The primary efficacy end points for comparison were final serum glucose concentrations,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics